How will pharmacovigilance look in 2030?
A key article from Guido Rasi, EMA’s Executive Director, Sabine Straus, the chair of EMA’s safety committee (PRAC) and Peter Arlett, the Agency’s Head of Pharmacovigilance and Epidemiology, published in Clinical Pharmacology and Therapeutics: Pharmacovigilance 2030. In 2030, regulators will dedicate significantly more time to engaging with patients and healthcare professionals and thus ensuring that the…